Fennec Pharmaceuticals Inc. (FRX.TO)
| Previous Close | 5.28 |
| Open | 5.50 |
| Bid | 5.30 x 0 |
| Ask | 5.35 x 0 |
| Day's Range | 5.28 - 5.50 |
| 52 Week Range | 4.95 - 13.25 |
| Volume | |
| Avg. Volume | 1,458 |
| Market Cap | 137.837M |
| Beta (5Y Monthly) | 0.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.80 |
| Earnings Date | Nov. 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down
Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.
- GlobeNewswire
FENC – Fennec Pharmaceuticals Inc. Investors Who Have Lost More Than $25,000 Are Encouraged To Contact Kehoe Law Firm, P.C. – Securities Class Action Investigation
PHILADELPHIA, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating whether Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) violated federal securities laws or engaged in other unlawful business practices. FENNEC INVESTORS WITH FINANCIAL LOSSES GREATER THAN $25,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE. On November 29, 2021, Fennec reported that “. . . it expects the U.S. Food and Drug Administration will not ac
- GlobeNewswire
Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) on November 29, 2021 from the U.S. Food and Drug Administration (FDA), after the PDUFA target action date of November 27, 2021, regarding its New Drug Application (NDA) for PEDMARK™ (a unique formulation of sodium thiosulfate), for intravenous administration for the prevention of ototoxicity associated w
